University Of Iowa Pharmaceuticals Added To Growing List Of Fervent Strategic Partners
Fervent Pharmaceuticals is pleased to announce the addition of University Of Iowa Pharmaceuticals (UIP) to its roster of strategic partners. Fervent continues to accelerate development of its innovative treatment for hot flashes and other vasomotor symptoms, and UIP will develop trial-scale batches of the product for its upcoming Phase II trial.
UIP is the largest and most experienced university-affiliated FDA-registered pharmaceutical manufacturing facility in the United States. UIP serves a broad spectrum of clients of all sizes in the pharmaceutical and biotechnology industries, and has performed work for pharmaceutical companies throughout the United States and the world.
Fervent CEO George Royster is excited about the partnership: “UIP offers Fervent the perfect blend of drug development expertise and experience. They’ve been practicing cGMP-compliant formulation development and product manufacturing for 40 years. I’ve been extremely impressed by their capabilities and their facility, which is the only one of its kind offering the range and scope of services needed by commercial clients like us.”
UIP joins previously announced strategic partners PMG Research and QuintilesIMS:
PMG Research is assisting with FP-101’s upcoming Phase II clinical trial beginning in 2017. PMG will spearhead patient recruitment, and the clinical trial will take place in their network of clinics across Illinois, North Carolina, South Carolina, and Tennessee.
QuintilesIMS has been an important strategic partner for Fervent since the earliest days of the company, contributing their many years of CRO experience and deep history with women’s health products. Their insights into the clinical trial process have been invaluable as they apply their expertise to Fervent’s imminent Phase II trials.